Clinical Trial Detail

NCT ID NCT04313504
Title Study Evaluating the Efficacy of Niraparib and Dostarlimab (TSR-042) in Recurrent/Metastatic HNSCC
Recruitment Not yet recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Trisha Wise-Draper
Indications

head and neck squamous cell carcinoma

Therapies

Dostarlimab + Niraparib

Age Groups: adult senior

No variant requirements are available.